Mandy Boontanrart - Ariya Bio
Reactivating fetal hemoglobin in B-Hemoglobinopathy patients
![Human Red Blood Cells](/en/industry/entrepreneurship/find-offers-programs-space-grants-for-entrepreneurs/pioneer-fellowship/2020/flipping-hemoglobine/_jcr_content/par/fullwidthimage/image.imageformat.930.2127556264.png)
B-Hemoglobinopathies are one of the most common genetic diseases worldwide with still no curative therapy other than allogeneic stem cell transplant. To address this, we are developing a CRISPR/Cas9 therapeutic approach to reactivate fetal hemoglobin that will ameliorate the disease symptoms. The genetic region we are targeting has not been proposed or explored for therapeutic benefit before.
![](/en/industry/entrepreneurship/find-offers-programs-space-grants-for-entrepreneurs/pioneer-fellowship/2020/flipping-hemoglobine/_jcr_content/par/textimage_1821646460/image.imageformat.text50percent.1436577299.jpg)
Mandy Boontanrart